Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Same-Day BLA Filings Show Pfizer Has Gained Ground On Novartis In Meningitis B

This article was originally published in The Pink Sheet Daily

Executive Summary

Both companies have “breakthrough” therapy designations from FDA and both announced BLA filings on June 17, but Pfizer’s earlier completion of the rolling submission could give it an edge in the race to launch a meningitis B vaccine in the U.S.

You may also be interested in...



Pfizer’s Meningitis B Vaccine Beats Novartis To Market, But ACIP Remains Key To Uptake

The first-mover advantage for Trumenba remains unclear as CDC’s Advisory Committee on Immunization Practices holds crucial sway on vaccine use and commercial success; ACIP will vote on use of meningitis B vaccines in high-risk groups and during outbreaks in February 2015, but more widespread use recommendations may not be issued until late next year.

Pfizer’s Meningitis B Vaccine Trumenba Is CBER’s First ‘Breakthrough’ Approval

FDA’s biologics center grants accelerated approval to the first U.S. vaccine targeting serogroup B meningococcal disease after a 4.5-month review; the vaccine is expected to come up for discussion, but not a vote, at CDC’s Advisory Committee on Immunization Practices meeting Oct. 30.

GlycoVaxyn Trialing New Vaccine Technology For Recurrent UTIs, Shigella

A new method of making vaccines, called bio-conjugation, may be more efficient and cost effective than chemical conjugation methods used by Pfizer for Prevnar and other vaccine makers, and it may address new pathogens too.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS077341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel